EE274 Estimated Costs of Adverse Event Management in NSCLC Patients with Epidermal Growth Factor Receptor Exon 20 Insertion Mutations Treated with Amivantamab or Mobocertinib after Progression on Platinum-Based Chemotherapy

Saved in:
Bibliographic Details
Published in:Value in health 2022-07, Vol.25 (7), p.S387
Main Authors: Vadagam, P, Vanderpoel, J, Khan, A, Malek, M, Musci, R, Zou, D
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
DOI:10.1016/j.jval.2022.04.520